Paper · 40103438
TREM2 scFv-Engineering Escherichia coli Displaying Modulation of Macrophages to Boost Cancer Radio-Immunotherapy.
Wang Y and 8 others. Adv Mater, 2025. Cited by 40 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. TREM2 scFv-Engineering Escherichia coli Displaying Modulation of Macrophages to Boost Cancer Radio-Immunotherapy. Papers, record 40103438. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40103438
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- TREM2 scFv-Engineering Escherichia coli Displaying Modulation of Macrophages to Boost Cancer Radio-Immunotherapy.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Escherichia coli | Major topic |
| Immunotherapy | Major topic |
| Single-Chain Antibodies | Major topic |
| Macrophages | Major topic |
| Receptors, Immunologic | Major topic |
| Membrane Glycoproteins | Major topic |
| Rectal Neoplasms | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Tumor Microenvironment | |
| Cell Line, Tumor |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| BE2022725 | Key Research and Development Program of Social Development of Jiangsu Province | PubMed | ||
| Priority Academic Program Development of Jiangsu Higher Education Institutions | PubMed | |||
| 32471443 | National Natural Science Foundation of China | PubMed | ||
| 32171382 | National Natural Science Foundation of China | PubMed | ||
| 32371461 | National Natural Science Foundation of China | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,865,133 | Context-dependent TREM2 signalling in myeloid cells: Molecular mechanisms and immunotherapeutic divergence in neurodegeneration and cancer. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42865133 | PubMed |
| 42,714,953 | TREM2: A Potential Target for the Targeted Therapy of Metabolic Diseases. | Mediators Inflamm | 2026 | https://conductscience.org/library/papers/42714953 | PubMed |
| 42,666,428 | Programmed Probiotics Generate Interleukin-37b-Bearing Nanovesicles In Situ for Precision Immunomodulation in Colitis. | Research (Wash D C) | 2026 | https://conductscience.org/library/papers/42666428 | PubMed |
| 42,639,448 | The microbiome-EBV axis in carcinogenesis bridges commensal influence and viral oncogenesis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42639448 | PubMed |
| 42,592,417 | Global research trends on the gut microbiota and immunotherapy for colorectal cancer: a bibliometric analysis. | Transl Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/42592417 | PubMed |
| 42,423,743 | Anti-PD-1 single-chain variable fragments in cancer immunotherapy: from molecular engineering to clinical translation. | Cancer Chemother Pharmacol | 2026 | https://conductscience.org/library/papers/42423743 | PubMed |
| 42,346,964 | Bacterial Outer Membrane Vesicles: Research Advances from Biogenesis Mechanisms to Engineered Applications. | Membranes (Basel) | 2026 | https://conductscience.org/library/papers/42346964 | PubMed |
| 42,185,884 | SUMOylation in cancer: molecular mechanisms and therapeutic implications. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42185884 | PubMed |
| 41,945,876 | Hierarchical Targeting of TREM2+ Myeloid Cells via Acid-Triggered OMVs Reprogram Immunosuppression and Suppress Osteolysis in Bone-Metastatic TNBC. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41945876 | PubMed |
| 41,776,613 | Spatiotemporal dynamics of radioresistance: decoding macrophage-driven radioprotective niches through temporal-spatial reprogramming. | Mol Cancer | 2026 | https://conductscience.org/library/papers/41776613 | PubMed |
1 to 10 of 22
See all 22 cited byGenes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TREM2 | 54,209 | PubTator's text mining | https://conductscience.org/library/genes/54209 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40103438
GET https://conductscience.org/api/papers/v1/40103438/cited_by?page=2